

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROVOCHOLINE® safely and effectively. See full prescribing information for PROVOCHOLINE®.

PROVOCHOLINE® (methacholine chloride) for inhalation solution, for oral inhalation use
PROVOCHOLINE® (methacholine chloride) inhalation solution, for oral inhalation use
Initial U.S. Approval: 1986

WARNING: SEVERE BRONCHOCONSTRICTION
See full prescribing information for complete boxed warning.

- Severe bronchoconstriction can result from Provocholine administration (including the lowest dose) (5.1)
- Use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV₁ < 60% predicted or adults with FEV₁ < 1.5 L (5.1)
- Use of Provocholine is not recommended in patients with clinically apparent asthma or wheezing (5.1)
- If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-Agonist) (5.1)

INDICATIONS AND USAGE

Provocholine, a cholinergic agonist used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma (1)

DOSAGE AND ADMINISTRATION

- The methacholine challenge test should be conducted in a pulmonary function laboratory or clinic, by adequately trained personnel, for safety and accuracy (2.1)
- Determine baseline FEV₁ values to assess whether a patient is able to undergo the methacholine challenge test (2.1)
- Recommended dosage(s) of Provocholine in the Methacholine Challenge Test is administration of increasing concentrations of Provocholine solution via nebulization (2.2)
- Administer using either the 5-Breath Dosimeter Dosing Method or the 2-Minute Tidal Breathing Dosing Method with the doubling or quadrupling stepwise protocols (2.4, 2.5)
- See the Full Prescribing Information for the required reconstitution and dilution procedures prior to use (2.3)
- See the Full Prescribing Information for the calculation and interpretation of the results (2.6)

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SEVERE BRONCHOCONSTRICTION

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Methacholine Challenge Test Overview
- 2.2 Recommended Dosage
- 2.3 Reconstitution and Dilution Prior to Administration
- 2.4 Administration with the Five (5)-Breath Dosimeter Dosing Method in Patients 5 Years of Age and
- 2.5 Administration with the Two (2)-Minute Tidal Breathing Dosing Method in Patients 5 Years of Age and Older
- 2.6 Calculation and Interpretation of Methacholine Challenge Test Results

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Risk of Severe Bronchoconstriction
- 5.2 Inadvertent Exposure to Healthcare Providers Administering Provocholine

DOSAGE FORMS AND STRENGTHS

- For inhalation solution: 100 mg methacholine chloride powder in amber glass vials (3)
- Inhalation solution: base solution (contains no methacholine chloride), 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL, each containing 3 mL of the concentrations of methacholine chloride per vial in a kit (3)

CONTRAINDICATIONS

- Known hypersensitivity to methacholine chloride or other parasympathomimetic agents (4)
- Baseline FEV₁ < 60% predicted (adults or children) or < 1.5 L (adults) (4)

WARNINGS AND PRECAUTIONS

Healthcare provider and any other personnel involved in the administration of the methacholine challenge test should take precautions to avoid inadvertent inhalation of Provocholine powder and nebulized aerosol (5.2)

ADVERSE REACTIONS

Adverse reactions associated with Provocholine include headache, throat irritation, light-headedness, and itching (6)

To report SUSPECTED ADVERSE REACTIONS, contact Methapharm at 1-866-701-4636 or call FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DRUG INTERACTIONS

- *Beta-Adrenergic Blockers*: May impair reversal of Provocholine-caused bronchoconstriction (7)
- *Beta-Agonists, Anticholinergics, and Theophylline*: Inhibit response to Provocholine; therefore, hold these drugs prior to Provocholine use (7)
- *Oral or Inhaled Corticosteroids, and Inhaled Cromoglycate*: May decrease response to Provocholine (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: Provocholine is not recommended (8.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA approved patient labeling.

Revised: 03/2022

5.3 Coexisting Diseases and Conditions

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

WARNING: SEVERE BRONCHOCONSTRICTION

Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV₁ < 60% predicted or adults with FEV₁ < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended [see *Warnings and Precautions (5.1)*].

Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β -agonist) [see *Warnings and Precautions (5.1)*].

If baseline spirometry is not performed or is measured inaccurately, the initial FEV₁ may be underestimated. In this situation, decreases in FEV₁ may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [see *Warnings and Precautions (5.1)*].

1 INDICATIONS AND USAGE

Provocholine, used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma.

2 DOSAGE AND ADMINISTRATION

2.1 Methacholine Challenge Test Overview

- Provocholine should be administered in a methacholine challenge test in a pulmonary function laboratory or clinic, by adequately trained personnel, for safety and accuracy, and should be performed only under the responsibility of a healthcare practitioner trained in and thoroughly familiar with all aspects of the technique of the test and the management of respiratory distress. Emergency medication and equipment should be immediately available to treat acute respiratory distress.
- Only consider Provocholine use in patients on chronic asthma drugs if the accuracy of the asthma diagnosis is in doubt. In these patients, only administer Provocholine if spirometry is normal after supervised withdrawal of the asthma drugs.
- Provocholine is not recommended for use in patients with clinically apparent asthma or wheezing.
- Before starting a methacholine challenge test, baseline spirometry must be performed. For a patient to be able to undergo the test, he or she must present with baseline FEV₁ (Forced

Expiratory Volume in 1 second) greater than or equal to 60% of the predicted value (in adults and children) and greater than or equal to 1.5 L (in adults).

- Do not use Provocholine in pediatric and adult patients with baseline FEV₁ < 60% predicted or in adults with FEV₁ < 1.5 L [see *Contraindications (4) and Warnings and Precautions (5.1)*].
- At commencement of the methacholine challenge test and prior to nebulization with Provocholine dose(s), FEV₁ must be measured following exposure to nebulized diluent or base solution (contains no methacholine chloride) to obtain the post-diluent FEV₁ [see *Dosage and Administration (2.4, 2.5)*].
- Provocholine powder for inhalation solution requires reconstitution and dilution before use (see *Reconstitution and Dilution Prior to Administration (2.3)*).
- Provocholine inhalation solution (in a ready-to-use kit) does not require reconstitution and/or dilution.
- Administer Provocholine by oral inhalation using either the 5-Breath Dosimeter Dosing Method or the 2-Minute Tidal Breathing Dosing Method with the doubling or quadrupling stepwise protocols [see *Dosage and Administration (2.4, 2.5)*].
- Discard any unused solution from the nebulizer after each administration.
- May use Provocholine with or without meals.
- The methacholine challenge test is considered positive if there is a reduction in FEV₁ of 20% or more from post-diluent FEV₁. The test should be stopped at this point. The reduction value must be calculated and recorded before starting the test with Provocholine (see *Calculation and Interpretation of Methacholine Challenge Test Results (2.6)*).
- An inhaled β agonist must be administered after a methacholine challenge test with Provocholine to expedite the return of the FEV₁ to baseline and to relieve any discomfort of the subject. Most patients revert to normal pulmonary function within 10 to 20 minutes following administration of a β agonist.

2.2 Recommended Dosage

The recommended dosage of Provocholine powder for inhalation solution (require reconstitution and dilution) or inhalation solution (in a ready-to-use kit) used in the methacholine challenge test administered via nebulization in adult and pediatric patients (5 years or older) is increasing concentrations of methacholine chloride solutions using either doubling or quadrupling dosing concentrations. Please refer to Table 3 for the doubling or quadrupling dosing concentrations.

2.3 Reconstitution and Dilution Prior to Administration

1. Provocholine Powder for Inhalation Solution requires reconstitution before use (see *Tables 1 and 2*):

Add 6.25 mL of 0.9% Sodium Chloride Injection (0.9% saline) or 0.9% Sodium Chloride Injection with 0.4% phenol (0.9% saline with 0.4% phenol) to the supplied vials containing 100 mg of Provocholine powder. Shake the vial to obtain a clear solution.

2. Dilute the reconstituted Provocholine solution:

Using sterile, empty USP Type 1 borosilicate glass vials, dilute the reconstituted Provocholine solution with 0.9% saline or 0.9% saline with 0.4% phenol either by doubling the concentration (see *Table 1*) or quadrupling the concentration (see *Table 2*). After adding the diluent, shake each vial to obtain a clear solution. Use the same diluent to prepare all concentrations

3. Use a sterile bacterial-retentive filter (porosity 0.22 μm) when transferring the reconstituted or diluted solution from each vial (at least 2 mL) to a nebulizer.
4. Refrigerate the reconstituted and diluted solutions at 36°F to 46°F (2°C to 8°C) for up to 2 weeks. Since the temperature of the solution affects nebulizer output, solutions should be taken out of the refrigerator and allowed to equilibrate to room temperature (approximately 30 minutes) before use.

Table 1: Reconstitution and Dilution of Supplied Provocholine powder for inhalation solution: Doubling Concentrations

TAKE	ADD 0.9% Saline or 0.9% Saline with 0.4% Phenol	Concentration (Total Volume) after reconstitution or dilution
100 mg of Provocholine Powder in one supplied vial	6.25 mL	16 mg/mL (6.25 mL) (Solution A)
3 mL of Solution A	3 mL	8 mg/mL (6 mL) (Solution B)
3 mL of Solution B	3 mL	4 mg/mL (6 mL) (Solution C)
3 mL of Solution C	3 mL	2 mg/mL (6 mL) (Solution D)
3 mL of Solution D	3 mL	1 mg/mL (6 mL) (Solution E)
3 mL of Solution E	3 mL	0.5 mg/mL (6 mL) (Solution F)
3 mL of Solution F	3 mL	0.25 mg/mL (6 mL) (Solution G)
3 mL of Solution G	3 mL	0.125 mg/mL (6 mL) (Solution H)
3 mL of Solution H	3 mL	0.0625 mg/mL (6 mL) (Solution I)

Table 2: Reconstitution and Dilution of Supplied Provocholine powder for inhalation solution: Quadrupling Concentrations

TAKE	ADD 0.9% Saline or 0.9% Saline with 0.4% Phenol	Concentration (Total Volume) after reconstitution or dilution
100 mg of Provocholine Powder in one supplied vial	6.25 mL	16 mg/mL (6.25 mL) (Solution 1)
3 mL of Solution 1	9 mL	4 mg/mL (12 mL) (Solution 2)
3 mL of Solution 2	9 mL	1 mg/mL (12 mL) (Solution 3)
3 mL of Solution 3	9 mL	0.25 mg/mL (12 mL) (Solution 4)
3 mL of Solution 4	9 mL	0.0625 mg/mL (12 mL) (Solution 5)

2.4 Administration with the Five (5)-Breath Dosimeter Dosing Method in Patients 5 Years of Age and Older

Prior to administering the Provocholine dose(s), determine the post-diluent FEV₁ value required for the methacholine challenge test .

Administration of the Diluent or Base Solution to Obtain Post-Diluent FEV₁ Value

1. *For the Provocholine powder for inhalation solution:*

- Using a 3 mL syringe and needle, draw up 2 to 3 mL of the same diluent used to reconstitute the Provocholine Powder (0.9% saline or 0.9% saline with 0.4% phenol) and dispense into the nebulizer using a sterile bacterial-retentive filter (porosity 0.22 µm).

For the Provocholine inhalation solution:

- Dispense the contents of a vial containing the base solution (contains no methacholine chloride) into the nebulizer.
2. Instruct the patient to hold the nebulizer upright with the mouthpiece in his/her mouth. The patient should wear a nose clip while inhaling from the nebulizer.
 3. At the end of exhalation during tidal breathing (functional residual capacity), instruct the patient to inhale slowly and deeply through the mouthpiece. Trigger the dosimeter soon after oral inhalation begins. Encourage the patient to continue inhaling slowly (about 5 seconds to complete the inhalation) and to hold the breath at total lung capacity (TLC) for another 5 seconds.

4. Repeat Step 3 for a total of five inspiratory capacity inhalations. Take no more than 2 minutes to perform these 5 inhalations.
5. Perform spirometry and measure the FEV₁ 30 and 90 seconds after the fifth inhalation from the nebulizer to obtain the post-diluent FEV₁ value. These values may be left at ambient (spirometer) temperature pressure saturated (ATPS). If the FEV₁ value is not of acceptable quality, repeat the procedure. If the post-diluent FEV₁ falls by $\geq 20\%$ from baseline FEV₁, do not give further inhalations and proceed to Step 8. If the post-diluent FEV₁ falls by $< 20\%$ from baseline FEV₁, continue to Step 6.

Administration of Provocholine in a Methacholine Challenge Test

6. For the Provocholine powder for inhalation:

Using a 3 mL syringe and needle, draw up the recommended Provocholine concentration (see *Table 3*) that was prepared using either the doubling or quadrupling dose method and dispense into the nebulizer using a sterile bacterial-retentive filter (porosity 0.22 μm). See Tables 1 and 2 for preparation of the Provocholine powder for inhalation solution.

Table 3: Recommended Provocholine Dose(s) By Nebulization [Doubling Dose(s) or Quadrupling Dose(s)]

Doubling Dose Increments	
Provocholine Concentration	Provocholine Dose*
0.0625 mg/mL (Solution I)	1.484 mcg
0.125 mg/mL (Solution H)	2.969 mcg
0.25 mg/mL (Solution G)	5.938 mcg
0.5 mg/mL (Solution F)	11.875 mcg
1 mg/mL (Solution E)	23.75 mcg
2 mg/mL (Solution D)	47.5 mcg
4 mg/mL (Solution C)	95 mcg
8 mg/mL (Solution B)	190 mcg
16 mg/mL (Solution A)	380 mcg
Quadrupling Dose Increments	
Provocholine Concentration	Provocholine Dose*
0.0625 mg/mL (Solution 5)	1.484 mcg
0.25 mg/mL (Solution 4)	5.938 mcg
1 mg/mL (Solution 3)	23.75 mcg
4 mg/mL (Solution 2)	95 mcg
16 mg/mL (Solution 1)	380 mcg

* Dose delivered based on the drug output of the English Wright Nebulizer and the duration of inhalation (2 minutes).

For the Provocholine inhalation solution:

Dispense the contents of a vial of the appropriate Provocholine concentration, starting with the lowest dose, into the nebulizer. The Provocholine solution concentrations, 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL, provided in the kit are ready-to-use. No further dilution is required.

7. Repeat steps 2 through 5 for each Provocholine concentration, emptying the nebulizer between each concentration. To keep the cumulative effect of Provocholine relatively constant, the time interval between the commencement of two subsequent concentrations should be kept to 5 minutes.
8. Stop dosing if the FEV₁ has fallen by $\geq 20\%$ from the post-diluent FEV₁, or the highest Provocholine concentration (16 mg/mL) has been administered (whichever comes first). Do not administer additional Provocholine concentrations if severe bronchoconstriction occurs [see *Warnings and Precautions (5.1)*].
9. After the test is completed, administer an inhaled β -agonist to the patient to expedite the return of the FEV₁ to within 90% of baseline and to relieve any discomfort (the majority of patients revert to normal pulmonary function within 5 minutes after β -agonist administration; in contrast the majority of patients revert to normal pulmonary function within 30-45 minutes without β -agonist administration). Wait 10 minutes and measure the FEV₁ and Vital Capacity. Patients should not be allowed to leave the laboratory until their FEV₁ has returned to within 90% of baseline.
10. After the test, wash and clean reusable nebulizers thoroughly according to manufacturer's recommendations.

2.5 Administration with the Two (2)-Minute Tidal Breathing Dosing Method in Patients 5 Years of Age and Older

Administer the diluent and the Provocholine dose(s) using the English Wright nebulizer or other suitable nebulizer as long as the device output and particle size are characterized.

Prior to administering the Provocholine dose(s), determine the post-diluent FEV₁ required for the methacholine challenge test.

Administration of the Diluent or Base Solution to Obtain Post-Diluent FEV₁ Value

1. *For the Provocholine powder for inhalation solution:*

Using a 3 mL syringe and needle, draw up 2 to 3 mL of the same diluent used to reconstitute the Provocholine powder (0.9% saline or 0.9% saline with 0.4% phenol) and dispense into the nebulizer using a sterile bacterial-retentive filter (porosity 0.22 μ m).

For the Provocholine inhalation solution:

Dispense the contents of a vial containing the base solution (contains no methacholine chloride) into the nebulizer.

2. Instruct the patient to relax and breathe the aerosol quietly (tidal breathing) for 2 minutes of inhalation time.
3. Place the face mask loosely over the nose and mouth or the mouthpiece in the mouth (with a nose clip) of the patient. The patient should hold the nebulizer to avoid warming the solution. Nebulizer should be kept upright and vertical.
4. Start the nebulizer by adjusting the flow meter so that the nebulizer is operating at the calibrated output (0.13 mL/minute for the English Wright nebulizer). Start the stopwatch immediately.
5. After exactly 2 minutes, turn off the flow meter, remove the face mask (or the mouthpiece from the mouth), and discard any remaining solution.
6. Perform spirometry and measure the FEV₁ 30 and 90 seconds after the end of the inhalation to obtain the post-diluent FEV₁. These values may be left at ambient (spirometer) temperature pressure saturated (ATPS). If the FEV₁ value is not of acceptable quality, repeat the procedure. If the post-diluent FEV₁ falls by $\geq 20\%$ from baseline FEV₁, do not give further inhalations and proceed to Step 9. If the post-diluent FEV₁ falls by $< 20\%$ from baseline FEV₁, continue to Step 7.

Administration of Provocholine in a Methacholine Challenge Test

7. For the Provocholine powder for inhalation solution:

Using a 3 mL syringe and needle, draw up the recommended Provocholine dose (see Table 3) using either the doubling or quadrupling dose method and dispense into the nebulizer using a sterile bacterial-retentive filter (porosity 0.22 μm). See Tables 1 and 2 for preparation of the Provocholine powder for inhalation.

For the Provocholine inhalation solution:

Dispense the contents of a vial of the appropriate Provocholine concentration, starting with the lowest dose, into the nebulizer. The Provocholine solution concentrations, 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg /mL, provided in the kit are ready-to-use. No further dilution is required.

8. Repeat steps 2 through 6 for each Provocholine dose, emptying the nebulizer between each dose. However, stop dosing if the FEV₁ has fallen by $\geq 20\%$ from the post-diluent FEV₁ or the highest Provocholine concentration (16 mg/mL) has been administered (whichever comes first). Do not administer additional Provocholine doses if severe bronchoconstriction occurs [see *Warnings and Precautions* (5.1)].

9. After the test is completed, administer an inhaled β -agonist to the patient to expedite the return of the FEV₁ to within 90% of baseline and to relieve any discomfort (the majority of patients revert to normal pulmonary function within 5 minutes after β -agonist administration; in contrast the majority of patients revert to normal pulmonary function within 30-45 minutes without β -agonist administration). Wait 10 minutes and measure the FEV₁ and Vital Capacity. Patients should not be allowed to leave the laboratory until their FEV₁ has returned to within 90% of baseline.
10. After the test, wash and clean reusable nebulizers thoroughly according to manufacturer's recommendations and discard disposable nebulizers appropriately.

2.6 Calculation and Interpretation of Methacholine Challenge Test Results

A positive methacholine challenge test is a $\geq 20\%$ reduction in the FEV₁ (after Provocholine oral inhalation) compared with the mean post-diluent FEV₁. Calculate and record post-diluent FEV₁ value before the methacholine challenge test is started. Express airway hyperreactivity as the provocative Provocholine concentration (mg/mL) providing a fall in FEV₁ of $\geq 20\%$ (PC₂₀) when the methacholine challenge test is dosed using either the 5-breath dosimeter method or the 2-minute tidal breathing method, or as the provocative Provocholine dose (mcg) providing a fall in FEV₁ of $\geq 20\%$ (PD₂₀) when using the 2-minute tidal breathing method.

Calculation of PC₂₀


Calculate PC₂₀ using one of the following methods. Determine the percent decrease in FEV₁ using the mean post-diluent FEV₁ and the lowest FEV₁ post-dose, as shown below:

$$\% \text{ fall in FEV}_1 = \frac{\text{mean post-diluent FEV}_1 - \text{lowest FEV}_1 \text{ post-Provocholine}}{\text{mean post-diluent FEV}_1} \times 100$$

Method #1

Plot the percent decrease in FEV₁ against the increasing methacholine concentration using a log scale and obtain the PC₂₀ by linear interpolation between the last two points, as shown in Figure 1.

Figure 1: Calculation of PC₂₀



Method #2

Alternatively, calculate the PC₂₀ as follows:

$$PC_{20} = \text{antilog} \left[\log C1 + \frac{(\log C2 - \log C1)(20 - R1)}{(R2 - R1)} \right]$$

Where:

- C1 = second last methacholine concentration (< 20% FEV₁ decrease)
- C2 = last methacholine concentration (≥ 20% FEV₁ decrease)
- R1 = % fall FEV₁ after C1
- R2 = % fall FEV₁ after C2

Calculation of PD₂₀ (2-minute tidal breathing method only)

Calculate the PD₂₀ as follows:

$$PD_{20} = \text{antilog} \left[\log D1 + \frac{(\log D2 - \log D1)(20 - R1)}{(R2 - R1)} \right]$$

Where:

- D1 = second last Provocholine dose (< 20% FEV₁ decrease)
- D2 = last Provocholine dose (≥ 20% FEV₁ decrease)
- R1 = % FEV₁ decrease after D1
- R2 = % FEV₁ decrease after D2

When using the English Wright nebulizer, refer to Table 2 for D1 and D2.

Interpretation of Results

A negative (normal) methacholine challenge result is defined as FEV₁ reduction of < 20% after all the doses (doubling or quadrupling dose increments) in Table 1 (for 5-breath dosimeter method) or Table 2 (for the 2-minute tidal breathing method) have been administered.

If asthma drugs are discontinued prior to the methacholine challenge test, consider the possibility of rebound airway hyperreactivity in the interpretation of the test results. The methacholine challenge test may occasionally be falsely positive after an influenza infection or upper respiratory infection, immunizations, in very young or very old patients, in patients with chronic lung disease (e.g., cystic fibrosis, sarcoidosis, tuberculosis, chronic obstructive pulmonary disease), in patients with allergic rhinitis without asthma symptoms, in smokers, or in patients after exposure to air pollutants.

3 DOSAGE FORMS AND STRENGTHS

- For inhalation solution: 100 mg of white to off-white crystalline powder in amber glass vials (powder is reconstituted and then diluted prior to administration)
- Inhalation solution:
 - base solution (contains no methacholine chloride/3 mL)
 - 0.0625 mg/mL (0.1875 mg/3 mL)
 - 0.25 mg/mL (0.75 mg/3 mL)
 - 1 mg/mL (3 mg/3 mL)
 - 4 mg/mL (12 mg/3 mL)
 - 16 mg/mL (48 mg/3 mL)

4 CONTRAINDICATIONS

Provocholine is contraindicated in the following:

- Hypersensitivity to methacholine or other parasympathomimetic agents. Reactions have included rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
- Baseline FEV₁ < 60% predicted (adults or pediatric patients) or < 1.5 L (adults).

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Severe Bronchoconstriction

Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV₁ < 60% predicted or adults with FEV₁ < 1.5 L. Emergency equipment and medication should be immediately available to treat acute respiratory distress. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended. If severe bronchoconstriction occurs, reverse immediately by the administration of a rapid-acting inhaled β-agonist.

If baseline spirometry is not performed or is measured inaccurately, the initial FEV₁ may be underestimated. In this situation, decreases in FEV₁ may not be detected after escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increase in the risk for excessive bronchoconstriction.

5.2 Inadvertent Exposure to Healthcare Providers Administering Provocholine

The supplied Provocholine powder or the Provocholine nebulized aerosol may cause bronchoconstriction in healthcare providers administering Provocholine in a methacholine challenge test. Healthcare providers and any other personnel involved in the administration of Provocholine should take the following precautionary steps:

- Do not inhale the supplied Provocholine powder
- Do not handle the Provocholine powder if you have asthma or hay fever
- Apply a low resistance filter to expiratory ports of dosing apparatus, as necessary, to prevent Provocholine release in the room air

5.3 Coexisting Diseases and Conditions

Provocholine is not recommended for patients with uncontrolled hypertension, aortic aneurysm, or history of myocardial infarction or stroke diseases. Patients with epilepsy, vagotonia, peptic ulcer disease, thyroid disease, urinary tract obstruction or other condition that could be adversely affected by a cholinergic agent should undergo methacholine challenge only if the healthcare practitioner considers the benefit to the individual outweighs the potential risks.

6 ADVERSE REACTIONS

The following adverse reactions associated with the use of Provocholine were identified in clinical studies or post marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Bronchospasm (includes symptoms such as chest tightness, cough, or wheezing).

Adverse reactions less commonly associated with Provocholine include headache, throat irritation, light-headedness, and itching.

7 DRUG INTERACTIONS

Beta-Adrenergic Blockers

The use of beta-adrenergic blockers may impair reversal of Provocholine-caused bronchoconstriction.

Beta-Agonists, Anticholinergics, and Theophylline

Beta-agonists, anticholinergics, and theophylline inhibit the response of airways to Provocholine; therefore, hold these drugs before Provocholine use for the following duration:

- Short-acting β -agonists (e.g., albuterol): 6 hours
- Long-acting β -agonists (e.g., salmeterol): 36 hours
- Short-acting anti-cholinergics (e.g., ipratropium): 12 hours
- Long-acting anti-cholinergics (e.g., tiotropium): ≥ 168 hours
- Oral theophylline: 12-48 hours

Oral or Inhaled Corticosteroids, and Inhaled Cromoglycate

Regular use of oral or inhaled corticosteroids and inhaled cromoglycate may acutely decrease bronchial responsiveness to Provocholine. However, these drugs may be continued with Provocholine use.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

The available data from published literature on Provocholine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies evaluating effects of methacholine chloride on embryofetal development have not been conducted. Diagnosis of bronchial airway hyperreactivity with bronchoprovocation challenge is not recommended for pregnant women because of the potential for hypoxia in the fetus. If bronchial airway hyperreactivity is suspected, consider trial of empiric treatment.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

8.2 Lactation

Risk Summary

There are no available data on the presence of methacholine chloride in human milk, the effect on the breastfed infant, or the effect on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Provocholine and any potential adverse effects on the breastfed infant from Provocholine or from the underlying maternal condition.

8.4 Pediatric Use

Provocholine is used in a methacholine challenge test for the diagnosis of bronchial airway hyperreactivity in pediatric patients 5 years of age and older who do not have clinically apparent asthma. The safety and effectiveness of Provocholine have not been established in pediatric patients below the age of 5 years.

8.5 Geriatric Use


The diagnosis of bronchial airway hyperreactivity is largely performed in pediatric and younger adult patients. Clinical studies of Provocholine did not include patients 65 years of age or older.

11 DESCRIPTION

Methacholine chloride, the active ingredient of Provocholine, is a parasympathomimetic (cholinergic) bronchoconstrictor agent. Provocholine (methacholine chloride) powder for solution is administered by oral inhalation.

Chemically, methacholine chloride (the active ingredient) is 1-propanaminium, 2-(acetyloxy)-N,N,N,-trimethyl-, chloride. It is a white to practically white deliquescent compound, soluble in water, alcohol, and chloroform and insoluble in ether. Aqueous solutions are neutral to litmus.

Methacholine chloride has an empirical formula of $C_8H_{18}ClNO_2$, a molecular weight of 195.69, and the following structural formula:



Provocholine Powder for Inhalation Solution:

Each vial of Provocholine contains 100 mg of methacholine chloride powder.

Provocholine Inhalation Solution Kit (Sterile):

Each kit is packaged in a carton with six plastic vials with twist-off cap each containing 3 mL of the following concentrations of methacholine chloride:

- a) base solution (contains no methacholine chloride)
- b) 0.0625 mg/mL (0.1875 mg/3 mL)
- c) 0.25 mg/mL (0.75 mg/3 mL)
- d) 1 mg/mL (3 mg/3 mL)
- e) 4 mg/mL (12 mg/3 mL)
- f) 16 mg/mL (48 mg/3 mL)

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Methacholine chloride is a cholinergic agonist. Bronchial smooth muscle contains significant parasympathetic (cholinergic) innervation. Methacholine chloride agonizes the muscarinic receptors which eventually induce bronchoconstriction.

12.2 Pharmacodynamics

After oral inhalation of Provocholine, patients with asthma are more sensitive to Provocholine-induced bronchoconstriction than are healthy subjects. This difference in response is the pharmacological basis for Provocholine in the methacholine challenge test.

12.3 Pharmacokinetics

There are no metabolic and pharmacokinetic data available on methacholine chloride.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There have been no studies with methacholine chloride that would permit an evaluation of its carcinogenic or mutagenic potential or of its effect on fertility.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

- Provocholine (methacholine chloride) Powder for Inhalation Solution: in amber glass vials that contain 100 mg of methacholine chloride powder, white to off-white in color. Cartons have 6 vials (NDC 64281-100-06).
- Provocholine (methacholine chloride) Powder for Inhalation Solution Pharmacy Bulk Package (not for direct use): in a plastic drum containing 1,000 g of methacholine chloride powder in a foil package (NDC 64281-100-07).
- Provocholine (methacholine chloride) Inhalation Solution Kit (Sterile): Each kit is packaged in a carton with six plastic vials with twist-off cap each containing 3 mL of the following concentrations of methacholine chloride:
 - a) base solution (contains no methacholine chloride)
 - b) 0.0625 mg/mL (0.1875 mg/3 mL)
 - c) 0.25 mg/mL (0.75 mg/3 mL)
 - d) 1 mg/mL (3 mg/3 mL)
 - e) 4 mg/mL (12 mg/3 mL)
 - f) 16 mg/mL (48 mg/3 mL)

Storage and Handling

- Powder for inhalation solution: Store the supplied powder at 59°F to 86°F (15°C to 30°C). Refrigerate the reconstituted and diluted solutions at 36°F to 46°F (2°C to 8°C) for up to 2 weeks [see *Dosage and Administration* (2.3)].
- Pharmacy bulk package: Store powder at 59°F to 77°F (15°C to 25°C), excursions permitted up to 86°F (30°C). Close package tightly after opening.
- Provocholine inhalation solution kit: Store between 59°F to 86°F (15°C to 30°C). Use immediately upon opening the vial.

17 PATIENT COUNSELING INFORMATION

Risk of Severe Bronchoconstriction

Inform the patient or caregiver that severe bronchoconstriction can result from Provocholine administration [*see Warnings and Precautions (5.1)*].

Cough, Chest Tightness, or Shortness of Breath

Inform the patient or caregiver that Provocholine may produce mild cough, chest tightness or shortness of breath.



Provocholine® powder for inhalation solution

Manufactured by:
Pancap Pharma Inc.
50 Valleywood Drive, Unit 6,
Markham, Ontario
Canada L3R 6E9

Manufactured for:
Methapharm, Inc.
11772 West Sample Road, Suite 101
Coral Springs, FL,
USA 33065

Provocholine® Solution for Inhalation Kit

Manufactured by:
Nephron Pharmaceuticals Corporation
4500 12th Street Extension,
West Columbia, South Carolina
USA 29172

For more information visit
www.provocholine.com,
email sales@methapharm.com
or call 1-833-887-7686.

®Provocholine is a registered trademark of Methapharm Inc.

February 2022